Loading organizations...
§ Private Profile · Petah Tiqva, HaMerkaz, Israel
Develops minimally invasive medical devices for structural heart conditions, tricuspid and mitral regurgitation.
Coramaze Technologies is a privately held medical device company, originating as a spin-off from the Western German Heart Center, with locations in Essen, Germany, and Petach-Tikva, Israel. The organization develops minimally invasive medical devices and catheter systems for treating structural heart conditions, specifically targeting tricuspid and mitral regurgitation through its proprietary TriPair and mitramaze valve repair technologies. Founded in 2013 by CEO Laura Figulla and Till Neumann, the enterprise is currently guided by board chair Rob ten Hoedt, a former executive at Medtronic. The business has raised a total of $6,510,000 in venture funding, which includes a $5,150,000 Series A round completed in 2015 and led by Elron Electronic Industries alongside HTGF. Additionally, the firm secured early capital through an EXIST research transfer grant to further advance its cardiovascular interventions for diverse patient populations.
Coramaze Technologies has raised $6.4M across 2 funding rounds.
Coramaze Technologies has raised $6.4M in total across 2 funding rounds.
Coramaze Technologies has raised $6.4M across 2 funding rounds. Most recently, it raised $5.1M Series A in September 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 2, 2015 | $5.1M Series A | Elron Ventures | High Tech Grunderfonds, SeedCapital Dortmund | Announced |
| Feb 14, 2014 | $1.4M Venture Round | High Tech Grunderfonds, SeedCapital Dortmund | — | Announced |
Coramaze Technologies has raised $6.4M in total across 2 funding rounds.
Coramaze Technologies's investors include Elron Ventures, High-Tech Grunderfonds, SeedCapital Dortmund.